Dublin, Feb. 07, 2023 (GLOBE NEWSWIRE) -- The "Benign Prostatic Hyperplasia Treatment Market Size Analysis Report by Type, End User - Industry Analysis Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
The BPH treatment market accounted for $11,892.8 million revenue in 2021, which is set to touch $18,837.7 million by 2030, progressing at a 5.2% CAGR from 2021 to 2030
This is owing to the growing cases of BPH, soaring preference for minimally invasive operations, and snowballing investments for research on novel treatments. As per Medscape, by the age of 60, approximately 50% of the men develop histopathologic BPH. By the age of 85, this percentage rises to 90%.
One way in which BPH management has significantly benefitted from advanced technology is the introduction of procedures that do not require general anesthesia or lengthy hospital stays. The prostate can now be fitted with a cutting-edge mechanical implant, which moves the invading lobes to a better position, to improve urine flow.
Minimally Invasive Procedures Are Gaining Wide Acceptance
Surgery is a superior option to treating BPH with medicine. However, patients tend to choose medication because of the post-operative harm that surgical incisions and burns can cause. Lately, patients' perceptions have changed as a result of the development of minimally invasive techniques, thus giving surgical equipment makers a competitive advantage.
Demand for Alpha-Blockers Rising among Patients
Around 85% of the market share was acquired for drug treatment in 2021. This is due to the rising demand for alpha-blockers, which help facilitate easier urine flow by relaxing the bladder neck muscles and the prostate.
Home Healthcare Settings Will Accumulate More Revenue
Home healthcare settings hold the larger market share, and they will experience a CAGR of over 5% in the coming years. This is owing to the rising number of patients who are being prescribed medications rather than surgical procedures. Additionally, a sizeable section of the populace favors drug-based home therapy over hospital care.
North America Widely Uses BPH Treatment
North America holds a 41% share of the global BPH treatment market. The problem's prevalence is rising, encouraging the use of cutting-edge treatments, including prostatic stenting, laser therapy, and UroLift therapy.
Additionally, there are a number of device and pharmaceutical companies in the region, and they are all keenly interested in undertaking R&D operations to improve the standard of care.
With a CAGR of 6.4%, the APAC region is predicted to grow the quickest. The progress is aided by the expanding standard of living, thriving per capita income and purchasing power, rising urological illness burden, and increasing healthcare investment.
The senior male population in Japan, China, and India is huge and needs constant medical care because of its high tendency for chronic illnesses.
Key Metrics
| Report Attribute | Details |
| No. of Pages | 378 |
| Forecast Period | 2021 - 2030 |
| Estimated Market Value (USD) in 2021 | $11892.8 Million |
| Forecasted Market Value (USD) by 2030 | $18837.7 Million |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
Company Profiles
- Astellas Pharma Inc.
- Alembic Pharmaceuticals Limited
- Unilab Inc.
- Pharex Health Corporation
- Biolitec AG
- Urologix LLC
- Advin Health Care
- Asclepion Laser Technologies GmbH
- Pnn Medical A/S
- Quanta Systems
- Abbott Laboratories
- Asahi Kasei Corporation
- Richard Wolf GmbH
- Boston Scientific Corporation
- KARL STORZ SE & Co. KG
- Teleflex Incorporated
- Olympus Corporation
- Pfizer Inc.
- Merck & Co. Inc.
- Eli Lilly and Company
- GlaxoSmithKline plc
- Allergan plc
- IPG Photonics Corporation
- Sanofi
- Allium Medical Solutions Ltd.
- SRS Medical
- Convergent Laser Technologies
Key Topics Covered:
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.5 Market Size Breakdown by Segment
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats
Chapter 3. Executive Summary
3.1 U.S.
3.2 Canada
3.3 Germany
3.4 France
3.5 U.K.
3.6 China
3.7 Japan
3.8 South Korea
3.9 India
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Definition of Market Segments
5.1 By Type
5.1.1 Drug Treatment
5.1.1.1 Alpha blockers
5.1.1.1.1 Alfuzosin
5.1.1.1.2 Doxazosin
5.1.1.1.3 Tamsulosin
5.1.1.1.4 Silodosin
5.1.1.1.5 Other alpha blockers
5.1.1.2 5-Alpha reductase inhibitors
5.1.1.2.1 Finasteride
5.1.1.2.2 Dutasteride
5.1.1.3 Others
5.1.2 Surgical Treatment
5.1.2.1 TURP
5.1.2.2 TUMT
5.1.2.3 TUNA
5.1.2.4 Laser therapy
5.1.2.5 Prostatic stenting
5.1.2.6 UroLift therapy
5.1.2.7 Rezum therapy
5.1.2.8 Others
5.2 By End User
5.2.1 Home Healthcare
5.2.2 Hospitals & Clinics
Chapter 6. Industry Outlook
6.1 Market Dynamics
6.1.1 Trends
6.1.1.1 Technological advancements
6.1.1.2 Product approvals and launches
6.1.2 Drivers
6.1.2.1 Increasing geriatric male population
6.1.2.2 Rising prevalence of BPH
6.1.2.3 Surging awareness of BPH disorders
6.1.3 Impact Analysis of Drivers on Market Forecast
6.1.4 Restraints
6.1.4.1 Side-effects associated with BPH medication
6.1.4.2 Unfavorable healthcare reforms
6.1.5 Impact Analysis of Restraints on Market Forecast
6.2 Impact of COVID-19
6.3 Porter's Five Forces Analysis
Chapter 7. Policy and Regulatory Landscape
7.1 Regulations for BPH Treatment Devices
7.2 Regulatory Framework for Drug Approval
7.2.1 U.S.
7.2.2 Europe
7.2.2.1 Centralized procedure
7.2.2.2 Mutual recognition procedure
7.2.2.3 Decentralized procedure
7.2.2.4 Nationalized procedure
7.2.3 Japan
Chapter 8. Global Market Size and Forecast
8.1 Overview
8.2 Market Revenue, by Type (2015-2030)
8.2.1 Global Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
8.2.1.1 Global benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
8.2.1.2 Global benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
8.2.2 Global Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
8.3 Market Revenue, by End User (2015-2030)
8.4 Market Revenue, by Region (2015-2030)
For more information about this report visit https://www.researchandmarkets.com/r/dwluai-prostatic?w=12
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
